Patient safety is of paramount importance to the pharmaceutical industry, the Association of the British Pharmaceutical Industry (ABPI) said today.
Industry is already required by legislation to undertake on-going monitoring of its medicines both during development and after launch.
The ABPI has not yet had the opportunity to look at the detail of the proposed changes and looks forward to taking part in the consultation process for the new legislation. It welcomes the introduction of any new legislation that provides further genuine protection for the patient, without simply adding unnecessary bureaucracy.
Since 2005, the international pharmaceutical industry has committed to the registration and publication of its clinical trials involving patients whether the outcomes are positive or negative – an initiative pioneered by the ABPI in 2003. Details of these trials can be found on an international portal established by the International Federation of Pharmaceutical Manufacturers’ Association (IFPMA).
For further information, please contact: ABPI Press office: 020 7747 1410 (office)